Russia is set to introduce a revolutionary cancer vaccine, developed using artificial intelligence (AI) and mRNA technology. The vaccine, designed to target malignant tumors based on a patient’s unique genetic profile, promises to be a breakthrough in cancer treatment.
Alexander Gintsburg, the director of the Gamaleya Research Institute of Epidemiology and Microbiology, confirmed that the experimental phase of the vaccine will begin in the coming months.
The vaccine will be administered in collaboration with two leading oncology institutions: the Hertsen Research Institute and the Blokhin Cancer Centre in Moscow. The Gamaleya Centre, known for creating the Sputnik V COVID-19 vaccine, developed this new cancer vaccine.
According to Gintsburg, the vaccine targets neo-antigens, a feature specific to individual tumors. This makes it a personalized treatment for each patient, unlike conventional drugs that can be used by anyone.
“This vaccine is created specifically for each patient based on their genetic needs, which cannot be replicated in other patients,” Gintsburg explained.
The vaccine’s first trial will focus on melanoma patients, with promising results from animal studies and initial human trials. The treatment process, assisted by AI, takes just one week, showcasing the advanced technology behind this innovation.
Russia’s Health Ministry reports around 4 million cancer patients in the country, with 625,000 new cases diagnosed each year.
This mRNA-based vaccine offers new hope to cancer patients, who often face difficult and expensive treatments. It is considered a major step forward in cancer care and could change the way oncological diseases are treated in the future.
The Gamaleya Centre is also working on developing similar vaccines for other cancers, such as pancreatic, kidney, and non-small-cell lung cancer.
With such advancements, Russia could lead the way in personalized cancer therapies in the near future.
In other news read more about ‘Made in Pakistan’ Insulin to Hit Local Market Soon
